Takeshi Hagiwara

Publications (2)2.47 Total impact

• Article: [Case of ulcerative colitis refractory to intravenous cyclosporine therapy successfully treated with infliximab].

  Ryosuke Tsuya, Satoshi Motoya, Hiroki Tanaka, Suguru Nakagaki, Hitoshi Nishioka, Takeshi Hagiwara, Hiroshi Kozawa, Sei Kurokawa, Tomonori Ambo, Akimichi Imamura
  [show abstract] [hide abstract]
  ABSTRACT: A 26-year-old woman was admitted to our hospital with relapse of ulcerative colitis (UC). We diagnosed it as a refractory UC because intravenous corticosteroid therapy had no effect. Intravenous cyclosporine therapy and other conventional therapies did not lead to remission. Then the possibility of infliximab was discussed with the patient and her parents and treatment with infliximab was started. Infliximab was infused intravenously at a dose of 5mg per kilograms of body weight. Immediately after the first infusion, clinical symptoms improved, and clinical remission was achieved within 12 weeks. It is suggested that infliximab can be effective for refractory UC.
  Nippon Shokakibyo Gakkai zasshi The Japanese journal of gastro-enterology 06/2008; 105(5):679-85.
• Source

  Available from: Mototsugu Kato

  Article: Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection.

  Takeshi Hagiwara, Mototsugu Kato, Tomonori Anbo, Akimichi Imamura, Toshihiro Suga, Takumi Uchida, Akira Fujinaga, Manabu Nakagawa, Soichi Nakagawa, Yuichi Shimizu, Jyunji Yamamoto, Hiroshi Takeda, Masahiro Asaka
  [show abstract] [hide abstract]
  ABSTRACT: To investigate the therapeutic effects of triple therapy combining lafutidine with clarithromycin and amoxicillin on H pylori infection and the resolution of gastroesophageal symptoms after eradication. We conducted a randomized, multicenter, open-label controlled trial to compare the effectiveness of a triple therapy of lafutidine, clarithromycin, and amoxicillin (lafutidine group) with that of a triple therapy of lansoprazole, clarithromycin, and amoxicillin (lansoprazole group) in patients with H pylori infection. The study group comprised 22 patients with gastric ulcers and 18 patients with duodenal ulcers who had H pylori infection. H pylori eradication rates were similar in the lafutidine group (14/20, 70%) and the lansoprazole group (14/20, 70%). Gastroesophageal reflux and abdominal symptoms improved after eradication therapy in both groups, whereas abdominal discomfort, diarrhea, and constipation were unchanged. H pylori status had no apparent effect on improvement of gastroesophageal reflux or abdominal symptoms after treatment. Adverse events were similar in both groups. The triple therapy including lafutidine is equivalent to triple therapy including lansoprazole in terms of H pylori eradication rates and improvement in gastroesophageal reflux and abdominal symptoms. These results are attributed to the fact that lafutidine has strong, continuous antisecretory activity, unaffected by CYP2C19 polymorphisms.
  World Journal of Gastroenterology 08/2007; 13(28):3836-40. · 2.47 Impact Factor